This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
ResMed (RMD) Gains From Mask Sales Amid Macro Headwinds
by Zacks Equity Research
ResMed's (RMD) respiratory care business continues to drive growth, courtesy of the adoption of bilevel and other non-invasive ventilator solutions worldwide.
Boston Scientific (BSX) Set to Acquire Relievant Medsystems
by Zacks Equity Research
Boston Scientific's (BSX) new M&A deal is likely to broaden the Neuromodulation business portfolio.
Align (ALGN) Gains From Growing Invisalign Volume, Innovation
by Zacks Equity Research
Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.
Medtronic (MDT) Gets CE Mark Approval for the New Simplera CGM
by Zacks Equity Research
Medtronic's (MDT) next-generation sensor Simplera receives CE Mark approval.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of its portfolio.
Abbott (ABT) to Commercialize Biosimilars in Emerging Markets
by Zacks Equity Research
Abbott (ABT) is set to commercialize several biosimilar molecules in key emerging markets via an expanded collaboration with mAbxience.
Orthofix (OFIX) Unveils Gemini System, Advances in Trauma Wing
by Zacks Equity Research
According to Orthofix (OFIX), with the launch of the Galaxy Fixation Gemini system surgeons now have efficient solutions for lower extremity trauma scenarios where time is an important factor.
Hologic (HOLX) Gains From New Launches as Macro Concerns Rise
by Zacks Equity Research
Hologic (HOLX) has been making impressive progress in its Breast Health arm, leveraging its strategic expansion efforts to diversify business across the patient continuum of care.
Abbott (ABT) Broadens Electrophysiology Footprint With TactiFlex
by Zacks Equity Research
The successful deployment of Abbott's (ABT) TactiFlex Ablation Catheter, Sensor Enabled in Canada broadens the company's global footprint in the electrophysiology space.
Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up
by Zacks Equity Research
Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.
Phibro (PAHC) Sales Impacted by Macro Concerns, FX Headwind
by Zacks Equity Research
The COVID-19 pandemic has adversely affected the international economic conditions and financial markets, leading to an economic downturn in many countries, in which Phibro (PAHC) operates.
Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and stable liquidity.
Teleflex (TFX) Rides on Urolift Prospects Amid Cost Pressures
by Zacks Equity Research
With respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting.
Teleflex (TFX) Picked for Vizient Innovative Technology Exchange
by Zacks Equity Research
Teleflex (TFX) gets selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange.
Alcon (ALC) Gains From Innovation & International Expansion
by Zacks Equity Research
Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.
Teleflex (TFX) New Survey Highlights BPH Impact Life Quality
by Zacks Equity Research
Teleflex's (TFX) survey results highlight how crucial it is for men to consult a urologist if they have strange or troublesome urine symptoms.
Charles River (CRL) Announces Partnership With Related Sciences
by Zacks Equity Research
Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.
Quest Diagnostics (DGX) to Aid Health Equity With New Pact
by Zacks Equity Research
Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.
Here's Why You Should Retain SmileDirectClub (SDC) Stock for Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub (SDC) on the latest technology enhancements and upbeat guidance.
Chemed (CHE) Faces Macroeconomic Woes, Tough Competition
by Zacks Equity Research
Inflationary trend, increased logistics costs and higher employee-related expenses continue to hurt Chemed's (CHE) growth.
Vicarious Surgical (RBOT) to Broaden User Network With New Deal
by Zacks Equity Research
Vicarious Surgical's (RBOT) partnership with Intermountain Health is likely to help the company gain access to Intermountain Health's extensive network.
CVS Health's (CVS) New COVID-19 Vaccine Available at Its Stores
by Zacks Equity Research
CVS Health's (CVS) updated mRNA COVID-19 vaccine is now available at all its pharmacy locations.
Walgreens (WBA) Expands Primary Care Research With New Pact
by Zacks Equity Research
Walgreens (WBA) will reach more communities quickly and provide comprehensive, cost-effective care with the new collaboration.